English version of Japanese guidance for use of biologics for psoriasis (the 2022 version)

J Dermatol. 2023 Feb;50(2):e41-e68. doi: 10.1111/1346-8138.16691. Epub 2022 Dec 29.


This is the English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). As the first biologics for psoriasis in Japan, infliximab and adalimumab, anti-tumor necrosis factor-α antibodies, became available in the field of dermatology in 2010, followed by ustekinumab, an anti-interleukin (IL)-12/IL-23p40 antibody, which was launched in Japan in 2011. Moreover, after 2015, three IL-17 inhibitors, the IL-17A antibody preparations secukinumab and ixekizumab, and an anti-IL-17 receptor antibody preparation brodalumab were marketed. Furthermore, after 2018, the anti-IL23p19 antibody preparations guselkumab and risankizumab, the TNF inhibitor certolizumab pegol, the IL-23 inhibitor tildrakizumab, and the anti-IL-17A/F antibody bimekizumab were marketed. It is important for physicians to select appropriate biologic therapy for each psoriatic patient after due consideration of disease factors, treatment factors, and patient background factors, sharing such information with patients. The followings can be listed as points to be considered for the selection of biologics: drug effects (e.g., strength of effectiveness, time to onset of effectiveness, effectiveness against arthritis, primary failure, secondary failure), safety (e.g., infections, administration-related reactions, and relationships with other comorbidities), convenience for patients (e.g., hospital visit intervals, self-injection, maintenance therapy at clinics, feasibility of drug discontinuation/re-administration), and payment (medical costs) borne by patients. This guidance has been prepared with the aim of allowing dermatologists experienced in the treatment of psoriasis to use biologics appropriately according to the circumstances of individual patients after consideration of the above-mentioned factors.

Keywords: biologics; guidance; interleukin 17; interleukin 23; psoriasis; tumor necrosis factor alpha.

MeSH terms

  • Adalimumab / therapeutic use
  • Biological Products* / therapeutic use
  • East Asian People
  • Humans
  • Interleukin-12
  • Psoriasis* / drug therapy
  • Psoriasis* / pathology
  • Treatment Outcome
  • Ustekinumab / therapeutic use


  • Biological Products
  • Ustekinumab
  • Adalimumab
  • Interleukin-12